Cargando…
SGLT2i‑treated heart failure patients with a reduced ejection fraction: A meta‑analysis
The aim of this study was to investigate the effects of SGLT2 inhibitors (SGLT2i) on patients with heart failure (HF) and reduced ejection fraction, with or without diabetes. A systematic review of randomized controlled trials (RCTs) was conducted, comparing SGLT2i to a placebo for HF patients. Rele...
Autores principales: | Ye, Qiang, Zha, Kelan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10623217/ https://www.ncbi.nlm.nih.gov/pubmed/37928504 http://dx.doi.org/10.3892/etm.2023.12248 |
Ejemplares similares
-
SGLT2i versus ARNI in heart failure with reduced ejection fraction: a systematic review and meta‐analysis
por: Yan, Yuling, et al.
Publicado: (2021) -
SGLT2 inhibitors in heart failure with reduced ejection fraction
por: Das, Uday Sankar, et al.
Publicado: (2021) -
Global Benefit of SGLT2 Inhibitors in Heart Failure With Reduced Ejection Fraction
por: Brownell, Nicholas K., et al.
Publicado: (2022) -
The dawn of the four-drug era? SGLT2 inhibition in heart failure with reduced ejection fraction
por: Genuardi, Michael V., et al.
Publicado: (2021) -
Retrospective analysis of SGLT2 inhibitors in heart failure with preserved ejection fraction
por: Clemmer, John S., et al.
Publicado: (2023)